Premium
Imatinib‐induced eruptive nevi
Author(s) -
Hamie Lamiaa,
Sawaya Rayah Touma,
Abbas Ossama
Publication year - 2021
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13491
Subject(s) - imatinib , imatinib mesylate , medicine , tyrosine kinase inhibitor , tyrosine kinase , dermatology , cancer research , cancer , receptor , myeloid leukemia
Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of a variety of oncological conditions. It has been associated with a spectrum of pigmentary cutaneous side effects. Despite the well‐known association of eruptive melanocytic nevi with the use of other tyrosine kinase inhibitors, this phenomenon has not been linked to the administration of imatinib. We present the first case of imatinib‐induced eruptive nevi in an 18‐year‐old patient with acute lymphocytic leukaemia in remission.